Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients
Recruiting
N/A
Interventional Study
Diabetes Mellitus
Constipation - Functional
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Constipation is the most common gastrointestinal manifestation in diabetic patients. Emerging evidence suggests that gut microbiota dysbiosis may contribute to the pathogenesis of diabetes, highlighting the need to investigate its role in diabetic constipation, though current research remains limited.
Current management of diabetic constipation primarily relies on bulk-forming and osmotic laxativ…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age: 18-70 years
* Type 2 Diabetes Diagnosis (per 2017 ADA criteria), meeting ≥1 of:
1. Fasting plasma glucose (FPG) ≥7.0 mmol/L
2. hour plasma glucose ≥11.1 mmol/L during 75g anhydrous oral glucose tolerance test (OGTT)
3. Random plasma glucose ≥11.1 mmol/L with hyperg…
Contacts